Expression of vascular endothelial growth factor receptor-2, epidermal growth factor receptor, cyclooxygenase-2, survivin, E-cadherin and Ki-67 in canine nasal carcinomas and sarcomas - a pilot study.
T-categories
chronic nasal discharge
computed tomography
cyclooxygenase inhibitors
dogs
immunohistochemistry
nasal tumors
tyrosine kinase inhibitors
Journal
Frontiers in veterinary science
ISSN: 2297-1769
Titre abrégé: Front Vet Sci
Pays: Switzerland
ID NLM: 101666658
Informations de publication
Date de publication:
2024
2024
Historique:
received:
19
02
2024
accepted:
29
07
2024
medline:
13
9
2024
pubmed:
13
9
2024
entrez:
13
9
2024
Statut:
epublish
Résumé
Malignant (intra-) nasal tumors (NTs) are the most common cause of chronic nasal discharge in dogs. Besides radiation therapy, palliative therapy is necessary in some dogs. Therefore, studies on receptor expression have supported the utility of tyrosine kinase inhibitors (TKI) in dogs with nasal carcinomas. However, studies on receptor expression in nasal sarcomas are lacking. This study evaluated the expression of vascular endothelial growth factor receptor-2 (VEGFR-2), epidermal growth factor receptor (EGFR), cyclooxigenase-2 (COX-2), Ki-67, survivin and E-cadherin in nasal carcinomas and sarcomas and compared it with tumor (T) categories based on computed tomography (CT). In 26 dogs with NTs, cross sectional imaging and upper airway endoscopy with guided biopsy collection were performed, followed by histopathological examination of NTs, revealing 19 epithelial and 7 mesenchymal tumors. While EGFR and E-cadherin were only expressed by carcinomas, the following markers were expressed by both carcinomas and sarcomas without significant differences between tumor types and T-categories: VEGFR-2 (carcinomas and sarcomas 100%), COX-2 (carcinomas 63%, sarcomas 57%), survivin (carcinomas 100%, sarcomas 86%) and Ki-67 (median expression of 28.5% in carcinomas and 17.3% in sarcomas). Based on similarities in marker expression between canine carcinomas and sarcomas, clinical studies should further elucidate the use of TKI or COX-2 inhibitors as additional therapy in dogs with nasal sarcomas.
Sections du résumé
Background
UNASSIGNED
Malignant (intra-) nasal tumors (NTs) are the most common cause of chronic nasal discharge in dogs. Besides radiation therapy, palliative therapy is necessary in some dogs. Therefore, studies on receptor expression have supported the utility of tyrosine kinase inhibitors (TKI) in dogs with nasal carcinomas. However, studies on receptor expression in nasal sarcomas are lacking.
Materials and methods
UNASSIGNED
This study evaluated the expression of vascular endothelial growth factor receptor-2 (VEGFR-2), epidermal growth factor receptor (EGFR), cyclooxigenase-2 (COX-2), Ki-67, survivin and E-cadherin in nasal carcinomas and sarcomas and compared it with tumor (T) categories based on computed tomography (CT).
Results
UNASSIGNED
In 26 dogs with NTs, cross sectional imaging and upper airway endoscopy with guided biopsy collection were performed, followed by histopathological examination of NTs, revealing 19 epithelial and 7 mesenchymal tumors. While EGFR and E-cadherin were only expressed by carcinomas, the following markers were expressed by both carcinomas and sarcomas without significant differences between tumor types and T-categories: VEGFR-2 (carcinomas and sarcomas 100%), COX-2 (carcinomas 63%, sarcomas 57%), survivin (carcinomas 100%, sarcomas 86%) and Ki-67 (median expression of 28.5% in carcinomas and 17.3% in sarcomas).
Conclusion
UNASSIGNED
Based on similarities in marker expression between canine carcinomas and sarcomas, clinical studies should further elucidate the use of TKI or COX-2 inhibitors as additional therapy in dogs with nasal sarcomas.
Identifiants
pubmed: 39268521
doi: 10.3389/fvets.2024.1388493
pmc: PMC11391428
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1388493Informations de copyright
Copyright © 2024 Pauly, Junginger, Oechtering, Hewicker-Trautwein and Rösch.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Comp Pathol. 2007 Jul;137(1):30-40
pubmed: 17467003
Am J Vet Res. 1976 Jul;37(7):851-6
pubmed: 937809
Res Vet Sci. 2017 Dec;115:484-489
pubmed: 28783596
J Vet Diagn Invest. 2000 Mar;12(2):111-7
pubmed: 10730938
Vet Radiol Ultrasound. 2009 May-Jun;50(3):330-5
pubmed: 19507402
Nat Med. 1997 Aug;3(8):917-21
pubmed: 9256286
Vet Comp Oncol. 2017 Sep;15(3):1041-1050
pubmed: 27278115
Can Vet J. 2008 Jan;49(1):71-6
pubmed: 18320982
Vet Rec. 2006 May 6;158(18):626-30
pubmed: 16679481
J Transl Med. 2008 Jan 03;6:1
pubmed: 18171482
Laryngoscope. 2001 Aug;111(8):1465-71
pubmed: 11568585
Vet Pathol. 2011 Jan;48(1):169-81
pubmed: 21160022
Vet Radiol Ultrasound. 2015 May-Jun;56(3):335-43
pubmed: 25703137
Head Neck. 2003 Oct;25(10):864-72
pubmed: 12966511
BMC Vet Res. 2024 Feb 3;20(1):44
pubmed: 38310231
Vet Comp Oncol. 2011 Jun;9(2):81-94
pubmed: 21569194
Acta Vet Hung. 2016 Mar;64(1):78-89
pubmed: 26919145
J Vet Med Sci. 2014 Nov;76(11):1505-12
pubmed: 25452259
J Comp Pathol. 2003 Jul;129(1):78-84
pubmed: 12859911
Can Vet J. 2015 Feb;56(2):185-92
pubmed: 25694669
Vet Comp Oncol. 2009 Jun;7(2):106-14
pubmed: 19453364
Cornell Vet. 1982 Apr;72(2):168-79
pubmed: 7083865
Pol J Vet Sci. 2015;18(1):113-22
pubmed: 25928918
J Small Anim Pract. 2009 Jul;50(7):334-40
pubmed: 19508490
Vet Comp Oncol. 2011 Jun;9(2):141-8
pubmed: 21569199
J Small Anim Pract. 2014 Mar;55(3):145-52
pubmed: 24423057
Vet Pathol. 1997 May;34(3):212-21
pubmed: 9163877
J Small Anim Pract. 2021 Oct;62(10):881-885
pubmed: 34131916
Vet Radiol Ultrasound. 1999 May-Jun;40(3):312-7
pubmed: 10519313
Res Vet Sci. 2010 Dec;89(3):409-14
pubmed: 20457460
Vet Pathol. 2017 Sep;54(5):783-791
pubmed: 28494700
Vet Comp Oncol. 2014 Sep;12(3):237-48
pubmed: 22994149
J Comp Pathol. 2005 Aug-Oct;133(2-3):155-63
pubmed: 16045921
J Comp Pathol. 2004 Jul;131(1):70-6
pubmed: 15144801
J Small Anim Pract. 2008 May;49(5):233-9
pubmed: 18373540
Folia Histochem Cytobiol. 2014;52(4):326-34
pubmed: 25511291
APMIS. 2003 Mar;111(3):430-8
pubmed: 12752223
J Am Vet Med Assoc. 2006 Aug 1;229(3):401-6
pubmed: 16881833
BMC Vet Res. 2020 Mar 24;16(1):97
pubmed: 32209084
Tierarztl Prax Ausg K Kleintiere Heimtiere. 2019 Apr;47(2):84-96
pubmed: 31013526
Genes Cancer. 2011 Dec;2(12):1097-105
pubmed: 22866201
Hum Pathol. 1999 Apr;30(4):458-66
pubmed: 10208469
Vet Pathol. 2022 May;59(3):415-426
pubmed: 35220825
J Vet Intern Med. 2007 Sep-Oct;21(5):1048-55
pubmed: 17939563
Vet Comp Oncol. 2012 Sep;10(3):194-205
pubmed: 22236194
J Clin Oncol. 2005 May 20;23(15):3568-76
pubmed: 15809453
J Histochem Cytochem. 1997 Nov;45(11):1455-9
pubmed: 9358847
Vet Pathol. 1993 Mar;30(2):146-54
pubmed: 7682367
Vet Pathol. 2011 Jan;48(1):254-65
pubmed: 20876365
Hum Pathol. 2013 Jul;44(7):1357-64
pubmed: 23375645
J Vet Intern Med. 2006 Jan-Feb;20(1):151-8
pubmed: 16496935
Vet Clin North Am Small Anim Pract. 1985 May;15(3):521-33
pubmed: 3892867
Int J Clin Exp Med. 2015 Sep 15;8(9):15675-83
pubmed: 26629062
Future Oncol. 2013 Oct;9(10):1459-67
pubmed: 24106897
Vet Radiol Ultrasound. 2017 May;58(3):315-325
pubmed: 28233364
Ann Oncol. 2012 May;23(5):1287-1292
pubmed: 21948811
J Small Anim Pract. 1999 Oct;40(10):473-8
pubmed: 10587924
Mol Cancer Ther. 2014 Jul;13(7):1777-1790
pubmed: 24755200
J Vet Sci. 2004 Mar;5(1):63-9
pubmed: 15028887
Vet Radiol Ultrasound. 2004 May-Jun;45(3):255-60
pubmed: 15200266
J Vet Diagn Invest. 2009 Nov;21(6):815-20
pubmed: 19901281
J Cancer Res Clin Oncol. 2013 Jun;139(6):1063-71
pubmed: 23525586
Vet J. 2008 Jun;176(3):408-10
pubmed: 17517527
Vet Pathol. 1978 Jan;15(1):18-30
pubmed: 625866
J Vet Intern Med. 2008 Jul-Aug;22(4):989-95
pubmed: 18647159
Vet Comp Oncol. 2022 Mar;20(1):293-303
pubmed: 34655275
J Vet Sci. 2010 Sep;11(3):249-55
pubmed: 20706033
Vet Radiol Ultrasound. 2004 Nov-Dec;45(6):577-81
pubmed: 15605853
Prostaglandins Leukot Essent Fatty Acids. 2005 Mar;72(3):181-6
pubmed: 15664302
Breast Cancer Res Treat. 2006 Jul;98(1):115-20
pubmed: 16538539
Pol J Vet Sci. 2014;17(2):375-7
pubmed: 24988869
J S Afr Vet Assoc. 2009 Dec;80(4):224-8
pubmed: 20458862
Med Oncol. 2014 Sep;31(9):170
pubmed: 25119503
Vet Pathol. 2001 Jul;38(4):427-35
pubmed: 11467477
Vet Comp Oncol. 2017 Jun;15(2):450-461
pubmed: 26833549
Acta Otolaryngol. 2005 Dec;125(12):1345-50
pubmed: 16303685